Financials in USD. Standardized financial statements.
A compact view of how Nxera Pharma Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $29.64B | $28.84B | $12.77B | $15.57B | $17.71B | $8.84B | $9.73B | $3.83B | $18.90B | $8.15B |
| Revenue Growth? | +2.8% | +125.9% | -18.0% | -12.1% | +100.3% | -9.1% | +154.0% | -79.7% | +131.9% | 0.0% |
| Cost of Revenue? | $8.21B | $7.62B | $3.10B | $926.00M | $933.00M | $761.00M | $851.00M | $1.82B | $0 | $4.00M |
| Gross Profit? | $21.44B | $21.22B | $9.66B | $14.64B | $16.78B | $8.08B | $8.88B | $2.01B | $18.90B | $8.15B |
| Gross Margin? | +72.3% | +73.6% | +75.7% | +94.1% | +94.7% | +91.4% | +91.3% | +52.5% | +100.0% | +100.0% |
| Operating Expenses? | $29.72B | $26.64B | $19.19B | $11.21B | $13.00B | $7.23B | $8.49B | $9.41B | $6.51B | $7.07B |
| Operating Income? | -$8.28B | -$5.42B | -$9.53B | $3.44B | $3.77B | $928.00M | $384.00M | -$7.40B | $12.39B | $1.07B |
| EBITDA? | -$3.91B | $105.00M | -$5.71B | $3.18B | $8.19B | $2.20B | $2.45B | -$6.76B | -$1.44B | $13.05B |
| Income Before Tax | -$14.96B | -$4.66B | -$10.68B | $1.08B | $433.00M | $1.62B | $534.00M | -$9.64B | $12.48B | -$3.30B |
| Income Tax Expense | -$2.42B | $176.00M | -$3.49B | $696.00M | -$584.00M | $143.00M | -$898.00M | -$1.69B | $2.84B | -$1.75B |
| Net Income? | -$12.54B | -$4.84B | -$7.19B | $382.00M | $1.02B | $1.48B | $1.43B | -$7.95B | $9.64B | -$1.55B |
| EPS? | $-139.60 | $-53.95 | $-87.18 | $4.67 | $12.53 | $18.78 | $18.69 | $-104.24 | $142.63 | $-25.27 |
| Diluted EPS? | $-139.60 | $-53.95 | $-87.17 | $4.63 | $12.40 | $18.61 | $18.48 | $-104.24 | $142.13 | $-25.27 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality